THERAPEUTIC DRUG MONITORING 
BY TANDEM MASS SPECTROMETRY

Complete Reagent Kits
Multilevel Calibrator Sets
Quality Controls

New Parameter Sets

Analyse up to 150 drugs 
with one kit.

> New: Antidepressants
> New: Antiepileptics
> New: Benzodiazepines
> Neuroleptics
> Psychostimulants

Tests are comprehensively validated for all 
tandem-MS with sufficient sensitivity.

For safe diagnostics worldwide.

Chromsystems GmbH · Munich · Germany
Phone: +49 89 18930-300 · Fax: +49 89 18930-399
www.chromsystems.de · mailbox@chromsystems.de
Information for Authors

Clinical Chemistry is published by the American Association for Clinical Chemistry (AACC). The journal welcomes contributions of original information, experimental or theoretical, that advance the science of clinical chemistry. Submissions should adhere to the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” (http://www.icmje.org/).

Manuscript Review. Manuscripts are evaluated by anonymous peer reviewers. Authors are usually notified of the disposition of a manuscript within three to four weeks of its receipt. Equal consideration is given to manuscripts in English from any country, whether or not the author is a member of the AACC.

Copyright. Manuscripts are considered with the understanding that each author has participated in the work and assumes responsibility for the content; that the authors have disclosed any potential conflicts of interest; that the same information has not been and will not be submitted for concurrent review, nor published elsewhere (other than as an abstract, preliminary report, or poster cited in the manuscript); that unique materials necessary to reproduce the results are available to readers; and that if the manuscript is accepted, copyright will be transferred to the publisher. To convey these assurances, all authors must sign the copyright form provided at acceptance.

Unpublished Work. When citing unpublished work or opinions of others, provide a permission letter from them.

Manuscript Preparation. Text: Most common word-processing software formats are accepted; Microsoft Word is preferred. Use 12-point font, 1-inch margins, and double spacing throughout. Do not use headers or footers, but do number the pages, starting with the title page as page 1. For guidance on manuscript preparation and style, consult our Information for Authors at http://www.clinchem.org/info_ar/info_authors.shtml.

Images: The acceptable image file formats for print publication are TIFF (tagged image file format) and EPS (encapsulated postscript) both at 600 dpi resolution. The figures must be submitted as independent files, not embedded within a word processing document. Microsoft PowerPoint (PPT) files are also acceptable, but each file must have embedded fonts and only one image per slide, one slide per file. Verify that symbols and lettering will be legible when reduced to publication size. Figures should be redesigned or recreated if they do not appear sharp and clear on paper. Authors are advised to use our online Digital Expert evaluation tool to test print figures before submitting them.

The author will be required to bear the full cost of the preparation and publication of color illustrations, invited contributions excepted. The charge for the first color figure is $1300. Subsequent color figures or parts of figures are $500 each.

Tables: Tables should be created in a common word-processing format. Spreadsheet-generated or embedded image tables should be recreated in the word-processing document and included with the text of the manuscript.


The complete Information for Authors is available at http://www.clinchem.org/info_ar/info_authors.shtml.

Clinical Chemistry (ISSN 0009-9147) is published monthly by the American Association for Clinical Chemistry, 1850 K Street, NW, Suite 625, Washington, DC 20006.

© 2011 The American Association for Clinical Chemistry
Quick Guide to Submission

For additional article types and detailed instructions, please see our Information for Authors at http://www.clinchem.org/info_ar/info_authors.shtml.

<table>
<thead>
<tr>
<th>Type of Submission*</th>
<th>Word Limit</th>
<th>Structured (S) or Unstructured (U)</th>
<th>Maximum Number of References</th>
<th>Total Number of Tables/Figures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Article</td>
<td>3,500</td>
<td>S: 250</td>
<td>40</td>
<td>6</td>
</tr>
<tr>
<td>Brief Communication</td>
<td>1,500</td>
<td>S: 250</td>
<td>20</td>
<td>1 each</td>
</tr>
<tr>
<td>Citation Classics</td>
<td>600</td>
<td>Nonapplicable</td>
<td>6</td>
<td>Nonapplicable</td>
</tr>
<tr>
<td>Clinical Case Study</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Case description</td>
<td>500</td>
<td>Nonapplicable</td>
<td>10</td>
<td>2</td>
</tr>
<tr>
<td>Case discussion</td>
<td>1,000</td>
<td>Nonapplicable</td>
<td>10</td>
<td>2</td>
</tr>
<tr>
<td>3-5 questions and up to 5 points to remember</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Case Study Commentary</td>
<td>300</td>
<td>Nonapplicable</td>
<td>Nonapplicable</td>
<td>Nonapplicable</td>
</tr>
<tr>
<td>Editorial</td>
<td>1,500</td>
<td>Nonapplicable</td>
<td>15</td>
<td>Nonapplicable</td>
</tr>
<tr>
<td>Letters to the Editor / Reply</td>
<td>750</td>
<td>Nonapplicable</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>Mini-Review</td>
<td>3,500</td>
<td>S: 250</td>
<td>40</td>
<td>4</td>
</tr>
<tr>
<td>Opinion</td>
<td>1,500</td>
<td>Nonapplicable</td>
<td>15</td>
<td>1</td>
</tr>
<tr>
<td>Perspective</td>
<td>1,500</td>
<td>Nonapplicable</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>Q&amp;A</td>
<td>3,500</td>
<td>Nonapplicable</td>
<td>Nonapplicable</td>
<td>Nonapplicable</td>
</tr>
<tr>
<td>Review</td>
<td>5,000</td>
<td>S: 250</td>
<td>75</td>
<td>6</td>
</tr>
<tr>
<td>What Is Your Guess?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Case description</td>
<td>75</td>
<td>Nonapplicable</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>Case discussion</td>
<td>75</td>
<td>Nonapplicable</td>
<td>5</td>
<td>1</td>
</tr>
</tbody>
</table>

*This chart represents common types of submissions to Clinical Chemistry.

**Manuscript Formatting**
- Double-spaced text, 1-inch margin, 12-point font size in Arial, Helvetica, or Times New Roman
- Numbered pages with references numbered sequentially in main text
- Title page listing title, authors (first name, middle initial, last name), each author’s affiliation during the study, corresponding author’s contact information, running title, keywords, list of any previous presentation of manuscript, and any disclaimers
- Reference list formatted according to Information for Authors with Journal abbreviations in the reference list checked against the National Center for Biotechnology Information database (http://www.ncbi.nlm.nih.gov/)
- SI units used throughout manuscript according to Information for Authors

**Metadata (to be entered online)**
- A valid and unique e-mail for each author
- Authors’ current institution, address, telephone, and fax
- Author Disclosure Forms and Contribution Forms to be completed by each author before submission. Copyright Transfer Agreement to be completed by each author after acceptance.
- Clinical Chemistry manuscript number of any companion papers (if applicable)

**Compliance with Guidelines**
- A MIQE checklist is required for all studies using quantitative real-time PCR experiments; a STARD checklist is required for all studies or trials of the diagnostic accuracy or performance of a diagnostic test; a CONSORT diagram is required for all randomized and Phase III trials; a MIAME checklist is required for all studies that present data for microarray experiments.
- All studies involving human study participants must indicate that they are in compliance with the Declaration of Helsinki ethical principles for medical research involving human study participants. A statement must be included in the text that Institutional Review Board approval was obtained and written informed consent obtained from study participants.

**Permissions**
- Written permission from the copyright holder is required to reproduce any copyrighted material
Abused Drugs III: A Laboratory Pocket Guide

John Wilson

2010, 131 pages, softcover
ISBN 987-1-59425-104-7
Product # 4622

Price only $20; AACC Member $16

Abused Drugs III: A Laboratory Pocket Guide incorporates an encyclopedic listing of drugs commonly seen in overdose. Information included extends from molecular structures and formulas and other common names to pharmacokinetic and metabolic data. Now grown to 200 substances, the guide represents a readily accessible one-stop source for available elimination and excretion information, extent of absorption, protein binding, and metabolism. Taken together the information represents a valuable tool for identifying and assessing the risk posed by the many medications and illicit substances encountered in the emergency rooms and clinical laboratories.

HOW TO ORDER

ONLINE:
http://www.aacc.org
and click on the AACC Store link

CALL:
(800) 892-1400
or (202) 857-0717

FAX:
(202) 887-5093

MAIL:
AACC Customer Service
1850 K Street NW, Suite 625
Washington, DC 20006

www.aacc.org
Justifying POCT in the ED: A Group A Strep Testing Case Study

Wednesday, October 19, 2011 ~ 2:00-3:00 pm Eastern U.S. Time

Although culture is the gold standard in testing for group A strep (GAS) infections, rapid antigen detection assays performed at the point-of-care have become the first line of testing for GAS infections in many physicians’ offices and hospitals. In busy pediatric EDs, the use of POC tests for group A strep can lead to greater efficiency in the diagnosis and treatment of patients presenting with symptoms consistent with a GAS infection.

During this webinar, you will hear how Children’s Hospitals and Clinics of Minnesota have benefited from implementing group A strep testing in their health system emergency departments. Two laboratorians and a pediatric ED physician will discuss why introducing rapid strep testing in the EDs made sense from a clinical standpoint, led to shorter ED visits and wait times, and improved patient satisfaction. You will also hear:

- What was involved in bringing group A strep testing into the EDs at Children’s
- How the decision impacted group A strep testing volumes, the laboratory’s workload, workflow in the lab and ED, and ED throughput
- The clinical significance of having rapid strep A testing available in the ED
- Expert advice on the value of rapid strep testing in a general ED versus a pediatric ED

The Experts:

**Kerstin Halverson, MS**, Point of Care Coordinator, Children’s Hospitals and Clinics of Minnesota, Minneapolis, MN

**Donna M. Milner, MD**, Pediatric Emergency Medicine Physician, Emergency Department, Children’s Hospitals and Clinics of Minnesota, St. Paul, MN

**Susan Simonton, MD**, Director of Clinical Laboratories, Children’s Hospitals and Clinics of Minnesota, St. Paul, MN

**Target Audience:** This program is designed for laboratory directors, managers, supervisors, point-of-care coordinators, and other laboratory, healthcare or in vitro diagnostic manufacturing professionals interested or involved in point-of-care testing for group A strep infections in the emergency department.

This program is approved by AACC for 1.0 Category 1 ACCENT credit hours.

*Learn how a major health system uses POCT to reduce length-of-stay in its pediatric ED population. Register today!*
Heart-type fatty acid binding protein (H-FABP) is a sensitive & specific biomarker of Myocardial Ischemia

- Early rise acute cardiac biomarker following the onset of ischemic episode
- Shows prognostic value across ACS spectrum (unstable angina, NSTEMI & STEMI patients)
- Significantly additive diagnostic & prognostic value to Troponin, even in the era of highly sensitive assays
- Predicts long-term mortality & reinfarction in Troponin negative patients


In USA - for research use only - pending 510K clearance

New Randox H-FABP Automated Assay enables rapid assessment on a wide range of immunoturbidimetric analysers

Learn more at www.randox.com/cardiology
Making Proficiency Testing Work for You

Wednesday, October 12, 2011 ~ 2:00-3:30 pm Eastern U.S. Time

Proficiency testing (PT) is once more becoming a hot issue in the lab community as CMS and CDC work on updating CLIA’s PT requirements. Potential changes include an expansion of the list of regulated analytes, new PT grading criteria, and a new mechanism for determining which analytes should be added or dropped from the regulated list.

The best way for labs to prepare for what lies ahead is to evaluate their existing PT practices and continue to focus on PT’s ultimate goal—ensuring accuracy and reliability in the testing process. During this program, CLIA’s administrator will provide an update on the upcoming proposed rule on PT, while a laboratorian who has worked on CAP’s Chemistry Resources Committee discusses new trends in proficiency testing and provides advice on how to best use PT as a quality management tool. In addition, you will know how to:

• Address common PT errors and investigate the causes of unexpected results or “near misses”
• Comply with the CLIA rules that govern proficiency testing and PT referral
• Take advantage of options offered by CMS for managing and addressing a PT failure
• Use an “accuracy-based” PT approach (in which a peer group uses a combination of PT material and fresh-frozen serum)

The Experts:
Robert Murray, JD, PhD, (Moderator), Director of Technology, Midwest Diagnostic Pathology, Park Ridge, IL

Judith Yost, MA, MT(ASCP), Director, Division of Laboratories, CMS, Baltimore, MD

Gary Horowitz, MD, Medical Director, Clinical Chemistry, Beth Israel Deaconess Medical Center, Boston, MA

Target Audience: This program is designed for laboratory directors, managers, supervisors, QA/QC professionals, compliance officers, and any others involved in performing or managing proficiency testing.

This program is approved by AACC for 1.5 Category 1 ACCENT credit hours.

Find out what changes await your lab in the proficiency testing arena. Register today!

TO REGISTER
Go to www.aacc.org and under “Events” select “Conference and Event Calendar.” Then, select this webinar. Once on the webinar page, click “Register” to register online or print a registration form.
Join us in family friendly Las Vegas for the latest edition of AACC’s Lab Automation conference series. Labs all over the world are facing many of the same challenges: integrating lab processes into an increasingly IT-focused healthcare world, improving efficiency and quality, assuring patient safety, and managing cost constraints. Attend this meeting and learn how fellow laboratorians have harnessed the power of automation to meet these challenges head on.

Here’s just a few of this year’s highlights:
- Uncovering what you don’t know: Asking the right questions when starting your lab automation project
- Planning ahead to minimize workarounds in the automated lab
- Metrics for the automated lab
- Integrating middleware and autoverification
- Unlocking the power of QC: Your key to lab excellence

Whether you’re facing the prospect of a new installation or looking to leverage your existing capacity, our expert faculty will be on hand to discuss the tips and strategies you’ll need to keep your lab automation projects on the road to success.

For more information or to register, go to the AACC web site at www.aacc.org or call AACC Customer service at (800) 892-1400 or (202) 857-0717.

For information on corporate partnership opportunities, please contact David Sainato at AACC (dsainato@aacc.org).
The Department of Pathology & Laboratory Medicine of Temple University School of Medicine and Temple University Hospital seeks a clinical-track faculty member to serve as Director of Clinical Chemistry. The Clinical Chemistry Lab supports services at the Main Core Lab, the Emergency Department Lab, the Cancer Center Lab, and multiple Points of Care, all located on the premises of Temple University Hospital. The successful candidate must possess an MD with Clinical Pathology board certification or a PhD and be a Diplomate of the American Board of Clinical Chemistry. Preference will be given to individuals with several years of experience in directing labs of comparably sized university/academic hospitals. The position will include teaching medical students and Pathology residents; research interests are expected and encouraged. The appointment may be made at any rank (Assistant, Associate or full Professor) depending on qualifications and experience.

Applicants should send their CV and a statement of personal and academic goals to: Yuri Persidsky, MD, PhD, Professor and Chair, Dept. of Pathology & Laboratory Medicine, c/o Julie Brissett, Senior Physician Recruiter & HR Administrator, Department of Physician Faculty Recruitment & Retention, Temple University School of Medicine, 3420 N. Broad Street, Medical Research Building, Suite 101, Philadelphia, PA 19140. Email: Julie.Brissett@tuhs.temple.edu

Temple University School of Medicine is an Affirmative Action/Equal Opportunity Employer and strongly encourages applications from women and minorities.

**AACC Mailing Lists**

**AACC Mailing Lists Are Available For:**
- Access To Members
- Access To Subscriber
- Access To Meeting Attendees

**AACC Mailing Lists Provide:**
- An Accurate Listing of Decision Makers in the Clinical Laboratory Field
- Current and Important Information That’s Essential to Your Marketing Efforts

Call or Fax:

American Association for Clinical Chemistry, Inc.
1850 K Street, Suite 625 • Washington, DC 20006
1-800-892-1400 • 202-857-0717 • Fax 202-887-5093

**Clinical Chemistry Reprints**

Authors may order reprints of their articles by contacting Ginger Larrimore
1-866-487-5625 or 410-943-3728

For commercial reprints, to increase your marketing visibility, contact Menna Burgess, Toll free
1-866-487-5625 ext. 3147 or 410-943-3147 or email: reprints2@cadmus.com

**Advertising Representatives**

Scherago International, Inc.

Director: Herbert L. Burklund
Traffic Manager: Qien Porter
Advertising Sales Manager: Mike Minakowski
Marketing Manager: Steve Hamburger

ADVERTISING CORRESPONDENCE: 525 Washington Blvd.
Suite 3310
Jersey City, NJ 07310
Tel (201) 653-4777
Fax (201) 653-5705

ADVERTISER

Chromsystems GmbH
CISBIO Bioassay
Diasonin
Immundiagnostik AG
Mindray
Randox Laboratories
Siemens Healthcare

PAGE NO.

2A
7A Abroad
16A
Cover 4
13A
9A
Cover2, Cover 3
Department of Laboratory Medicine and Pathology, Faculty Position

The Department of Laboratory Medicine and Pathology, Division of Clinical Core Laboratory Services at Mayo Clinic in Rochester, MN is seeking an M.D. or Ph.D., board certified in clinical pathology and/or clinical chemistry, to help support clinical activities in the Cardiovascular Laboratory Medicine (CVLM) Risk laboratory, the Hospital Clinical and Pediatric Laboratories, point-of-care testing and Phlebotomy. The CVLM Laboratory is responsible for all cardiovascular testing (e.g., lipids, inflammatory markers) and provides extensive opportunities for test development activities. The Hospital Clinical and Pediatric Laboratories support the clinical missions of Saint Mary’s Hospital and Rochester Methodist Hospital predominantly with tests requiring a rapid turn around time. POC testing is extensive and requires close physician monitoring and Phlebotomy for the entire institution (both in and outpatient) is part of the Division’s mission.

The successful applicant, in addition to manifesting clinical expertise, will be expected to participate in a major way in clinical and/or laboratory research (preferred) and/or pathology resident and clinical chemistry fellow education, and/or administrative activities. Mayo’s large, diverse patient population and medical/surgical specialty programs offer unique opportunities for clinical investigation. Mayo Clinic is a non-profit, physician-led clinical practice integrated with education and research in a unified multi-campus system. To learn more about Mayo Clinic or Rochester, MN, please visit www.mayoclinic.org/labmed-pathology-rst

Applicants should have a strong interest in general clinical pathology and/or clinical chemistry and the activities indicated above. Previous experience in laboratory medicine is required. Academic rank and salary will be commensurate with experience. Opportunities for advancement academically and to leadership positions exist and are dependent upon the applicant’s experience and performance. The position is available immediately and applications will be accepted until the position is filled. Curriculum vitae, a cover letter detailing relevant experience and major accomplishments, and the names of three individuals who can provide letters of recommendation should be sent to:

Allan S. Jaffe, M.D.
Chair, Clinical Core Laboratory Services
Department of Laboratory Medicine and Pathology
Mayo Clinic
200 First Street SW • Rochester, Minnesota 55905
Fax: 507-284-3680 • Email: jaffe.allan@mayo.edu

Mayo Foundation is an affirmative action and equal opportunity employer and educator. Post-offer/pre-employment drug screening is required.
**Director, Clinical Chemistry/Toxicology**

The Department of Pathology at The Ohio State University Medical Center in Columbus, OH, is seeking an individual with an MD or PhD for the role of Director of Clinical Chemistry/Toxicology. The successful candidate will be required to (1) provide medical and technical oversight to all appropriate areas of the clinical laboratory which includes general and specialized chemistry testing and toxicology, (2) develop a basic or applied clinical research program and (3) participate in the teaching responsibilities of the department to include graduate students, medical students, residents, and fellows. Candidates with board certification or eligibility by the American Board of Pathology with training and experience in clinical chemistry are encouraged to apply. The successful candidate must also demonstrate effective communication skills and a strong customer-service focus. A clinical or academic University appointment in the Department of Pathology is available to the qualified applicant with academic rank commensurate with experience and scholarly achievement.

The Ohio State University Medical Center is a tertiary health care facility of 1140 beds located on two campuses. The Department of Pathology offers excellent opportunities for career development including opportunities for collaborative research with faculty in both the clinical and basic science departments within the medical center. The Ohio State University is an equal opportunity, affirmative action employer. Women, minorities, Vietnam-era veterans, disabled veterans and individuals with disabilities are encouraged to apply. Please send a letter of application with a statement of research interests, a brief description of career goals, curriculum vitae, and four names and addresses for letters of recommendation to:

Amy Gewirtz, M.D.  
Medical Director, Clinical Laboratories  
Ohio State University Medical Center  
410 W. 10th Avenue, Room E310A Doan Hall  
Columbus, OH  43210  
E-Mail: amy.gewirtz@osumc.edu

**Associate Director, Clinical Pathology Laboratories**

The Department of Pathology at The Ohio State University Medical Center in Columbus, Ohio, is seeking an individual with an MD or PhD for the role of Associate Director of the Clinical Pathology Laboratories. The successful candidate will be required to (1) provide medical and technical oversight to appropriate areas of the clinical laboratory to include general chemistry, point of care and hematology testing, (2) develop a basic or applied clinical research program and (3) participate in the teaching responsibilities of the department to include graduate students, medical students, residents, and fellows. Candidates with administrative leadership experience are encouraged to apply. Board certification by the American Board of Pathology in clinical pathology is required with subspecialty training in chemistry, hematology or transfusion medicine preferred. In addition, the applicant must also demonstrate effective communication skills and a strong customer-service focus. A clinical or academic University appointment in the Department of Pathology is available to the qualified applicant with academic rank commensurate with experience and scholarly achievement.

The Ohio State University Medical Center is a tertiary health care facility of 1140 beds located on two campuses. The Department of Pathology offers excellent opportunities for career development including opportunities for collaborative research with investigators in the Department of Internal Medicine as with other faculty in both the clinical and basic science departments within the medical center. The Ohio State University is an equal opportunity, affirmative action employer. Women, minorities, Vietnam-era veterans, disabled veterans and individuals with disabilities are encouraged to apply. Please send a letter of application with a statement of research interests, a brief description of career goals, curriculum vitae, and four names and addresses for letters of recommendation to:

Amy Gewirtz, M.D.  
Medical Director, Clinical Laboratories  
Ohio State University Medical Center  
410 W. 10th Avenue, Room E310A Doan Hall  
Columbus, OH  43210  
E-Mail: amy.gewirtz@osumc.edu
Faculty position for Test Development in Clinical Laboratories
Indiana University Health Pathology Laboratory
Department of Pathology and Laboratory Medicine
Indiana University School of Medicine

The Department of Pathology and Laboratory Medicine of Indiana University School of Medicine and the Indiana University Health Pathology Laboratory invite applications for a full-time faculty position for test development in clinical laboratories with academic track and rank commensurate with experience and scholarly achievement.

Indiana University Health is a health system consisting of 16 hospitals in Indianapolis and across Indiana. The Indiana University Health Pathology Laboratory (IUHPL) processes more than 10 million tests annually. The clinical operations at the IUHPL have experienced tremendous growth and demand continuous development of clinical tests in existing and novel platforms to meet the changing needs of patient care. A development core in the IUHPL has been established to fulfill this goal and the faculty member will work within the capacity of the development core.

Qualified candidates will hold a doctoral position in medical or biological sciences with additional trainings or experiences in areas related to diagnostic pathology, laboratory medicine, clinical chemistry, or molecular pathology. The ideal candidate should have a passion for research development and will be able to work as a bench scientist with strong analytic skills and knowledge in common laboratory methods and instruments. Experience and expertise in the practice of diagnostic assays in a clinical setting (human or veterinary medicine) is highly desirable. Excellent organizational and time-management skills are required, as is the ability to prioritize, manage and integrate multiple responsibilities. The candidate is also expected to have strong verbal and written communication skills and to be able to teach and train staff members for new technology. It is essential that the candidate should be able to take a collaborative working approach and to work in a team to achieve program goals with minimal supervision.

Responsibilities include 1) planning, developing and teaching analytically validated assays based on existing or novel platforms; (2) demonstrating assay fitness and robustness for purpose in clinical use, (3) establishing standard operating procedure for transfer into routine laboratory operations, (4) providing management to ensure the successful progress of the project and implementation of the assay; 5) collaborating and interacting with internal and external physicians and scientists for test development and applications.

The position is available immediately. Applications will be evaluated upon receipt and will be accepted until the position is filled. The salary and benefit package will be consistent with the experience and training. Indiana University is the sole medical school in the state of Indiana. Indianapolis is a thriving city with a vibrant downtown community, outstanding cultural and sports facilities, beautiful suburbs and a low cost of living.

Applicants should forward curriculum vitae, statements of career goals and academic interests and the names and contact information of three references, to:

John N. Eble, M.D., M.B.A.
Nordschow Professor and Chairman
Department of Pathology and Laboratory Medicine
jeble@iupui.edu

Indiana University is an Affirmative Action/Equal Opportunity Employer, M/F/D
Follow the Leader in Vitamin D Testing

For 25 years DiaSorin has been setting the standard.

The DiaSorin LIAISON® offers a fully automated, high throughput, cleared assay that measures both D2 and D3 for a TOTAL 25 Vitamin D result.

LIAISON®
25 OH Vitamin D TOTAL Assay

During the past two decades, DiaSorin assays have been used in the vast majority of clinical studies worldwide to define normal circulating 25(OH)D levels.

- National Health and Nutrition Examination Survey (NHANES III)
- Nurses’ Health Study (NHS)
- Women’s Health Initiative (WHI)
- Health Professionals’ Follow-up Study (HPFS) by Harvard

More than 125 million Vitamin D tests distributed worldwide

For more information contact us at 800-328-1482 or info@diasorin.com.
Critical Issues in Alcohol and Drugs of Abuse Testing

Edited by Amitava Dasgupta

2009, 319 pages, softcover
ISBN 9781594250934
Product # 5629
Price only $90; AACC Member $75

Critical Issues in Alcohol and Drugs of Abuse Testing addresses problems encountered in workplace alcohol and drug testing and how to resolve such problems. People try to pass drug tests by using a variety of urinary adulterants, and this book reviews, in detail, how to catch these cheaters. Ingestion of certain prescription medications or poppy seed-containing food, however, may also cause positive results in drug testing. Two chapters are devoted to reviewing true analytical positive results in drugs of abuse testing. In addition, drug testing using alternative specimens such as hair, saliva, and sweat is also addressed. Additional chapters review the following:

- Pharmacogenomics of alcohol abuse
- Pharmacogenomics of drugs of abuse
- Abuse of magic mushrooms, peyote cactus, khat, and volatiles
- Sports drug testing

Critical Issues in Alcohol and Drugs of Abuse Testing will be helpful to toxicologists, medical review officers, pathologists, and medical technologists as a quick handbook and reference book to address problems encountered in alcohol and drugs of abuse testing.

HOW TO ORDER

ONLINE:  http://www.aacc.org and click on the AACC Store button

CALL:  (800) 892-1400 or (202) 887-0717

FAX:  (202) 887-5093

MAIL:  
AACC Customer Service  
1850 K Street NW, suite 625  
Washington, DC 20006
New Edition!

Biochemical and Molecular Basis of Pediatric Disease, 4th Edition

Edited by Dennis J. Dietzen, Michael J. Bennett, and Edward C. C. Wong

2010, 660 pages, softcover
ISBN 978-1-59425-100-9, Product # 6114
Price only $124; AACC Member $99

For many years Biochemical Basis of Pediatric Disease, 3rd Edition, edited by Drs. Soldin, Rifai, and Hicks, has served as the critical standard for pediatric clinical laboratory medicine. This new edition, retitled Biochemical and Molecular Basis of Pediatric Disease, 4th Edition, continues the previous edition’s strong focus on understanding the pathogenesis of pediatric disease, emphasizing not only the important role of the clinical laboratory in defining parameters that change with the disease process, but also the molecular basis of many pediatric diseases.

Biochemical and Molecular Basis of Pediatric Disease, 4th Edition, includes new chapters in the areas of neonatology, iron metabolism, coagulation, endocrinology, and allergy. All other chapters have been extensively updated, covering nearly all aspects of pediatric disease and the many advances that have been made in recent years. Fifty-two pediatric academic faculty, all nationally known for their pediatric clinical and laboratory expertise, have contributed to this new edition, designed not only for trainees in pediatrics and laboratory medicine, but also for well-established practitioners who wish to keep up with advances in the field and those who would like to better understand the unique aspects of pediatric disease and the clinical laboratory.

www.aacc.org

Edited by Christopher P. Price, Andrew St John, and Larry J. Kricka
2010, 593 pages, softcover
ISBN 987-1-59425-103-0   Product # 6117
Price only $124; AACC Member $99

Point-of-care testing (POCT) is now considered a key enabler of reform and quality improvement in healthcare. Written by an international list of authors, this book brings together:

- A distillation of the key challenges in healthcare today, including the move to patient-centered care
- Analytical principles of POCT technology and the new developments in this field
- How to manage an effective POCT service in a changing environment
- Applications of POCT in a range of clinical settings and the improved outcomes that results from POCT
- A discussion of the challenges of translating innovative technology in the complex environment of healthcare, and the leading role that POCT will play in transforming healthcare delivery.

The technological developments described in this book demonstrate how all in vitro tests can potentially be delivered at the point of care in the future. The challenge for developer, manufacturer, purchaser, provider and user is to determine which tests will offer the greatest benefit and address the challenges of healthcare delivery. As a disruptive technology, experience indicates that the biggest challenge for all stakeholders will be transforming the practice of healthcare in order to generate these benefits. This is a ‘must read’ book for all developers and manufacturers of POCT technology, those who develop healthcare policy, those who purchase or commission healthcare services, and those who will use this innovative technology.
Clearly, Cisbio's 10 year experience makes a big difference when I use their new ELISA Chromoa for the diagnosis and follow up of neuroendocrine tumors.

Get excellence in chromogranin A measurement

- Secure patient follow-up:
  Intra-assay CVs <6%
  Inter-assay CVs <10%
- Reliable diagnosis:
  Thanks to highly specific antibodies against the unprocessed central domain of CGA (145–245)
- Straight forward seric test:
  A strong alternative to urinary reference markers for convenient patient care
- Ten years of experience in CgA immunoassays

International office:
+33 169 857 253 - iva@cisbio.com
www.iba-worldwide.com - www.ria-cis.com
US and Japan for research use only
Testing for vitamin D has always been a complicated process. Now labs can test for total 25(OH) vitamin D (D₃ and D₂) in 18 minutes or less on the ADVIA Centaur® family of instruments — quickly, accurately, and with full automation.

This new assay arrives just in time. Demand for vitamin D testing continues to grow, prompted by emerging research on the importance of vitamin D to wellness.

With the new Siemens equimolar Vitamin D Total assay, testing is within the reach of labs of all sizes. That means physicians and patients can benefit from getting their vitamin D testing results faster. And it means labs will be better prepared to meet today’s demands — and tomorrow’s.

Learn more about how the new ADVIA Centaur Vitamin D Total assay is a viable solution for your lab by downloading educational white papers at www.siemens.com/vitamindtotal

*Not available for sale in the U.S.

Answers for life.
How can I expand my lab’s capabilities but not my budget?

Siemens offers flexible systems and a versatile assay portfolio to increase capacity without straining your resources.

With our diverse range of immunoassay, clinical chemistry, and integrated platforms, you can enhance your operational efficiency while seamlessly meeting ongoing demands. And, together with our comprehensive disease-state menu, Siemens enables you to focus on what matters most—improving service to clinicians and care to patients. Find out more at www.usa.siemens.com/diagnostics

NEW! Dimension EXL® 200 Integrated Chemistry System

Answers for life.
1,25-(OH)$_2$-Vitamin D$_3$/D$_2$

Virtually no ion suppression
Complete removal of interfering matrix components

Easy ID ImmunoTube® extraction
No derivatization, precipitation or SPE-extraction

Flexible use on high-end instruments
- ThermoScientific (TSQ Quantum Vantage Triple Quadropole)
- AB SCIEX (Q Trap® 5500 LC-MS/MS with Turbo V™ Source)
- Waters (Quattro Premier XE and Xevo TQS)

Published & market proven

Lembcke et al., 2011:
„Fast, robust and reliable method for the determination of 1,25(OH)$_2$ vitamin D₃...“
[AB SCIEX Poster, ASMS conference, June 5-9]

Yuan et al., 2011:
„An LC-MS/MS-based method [...] suitable for clinical testing. Both D₃ and D₂ were quantified with high selectivity and sensitivity.“

He et al., 2011:
„This off-line purification approach is very specific and robust. No interference or ion suppression was observed.“
[ThermoScientific Poster, ASMS conference, June 5-9]